fbpx
  • Systems
  • Applications
  • News & Events
  • About
    • Careers
  • Contact
    • Distributor Login
Celsee
  • Systems
  • Applications
  • News & Events
  • About
    • Careers
  • Contact
    • Distributor Login

News

Celsee Diagnostics, IncellDx Announce Immuno-Oncology Research Agreement

Collaborative studies will focus on the use of circulating tumor cells (CTCs) as a biospecimen for PD-L1 quantification and as a tool for tailoring therapy in metastatic lung cancer. Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy and rare-cell detection products, and IncellDx, a single-cell diagnostic company offering transformative diagnostic and prognostic clinical patient information based on a reagent platform allowing simultaneous, quantitative single cell-analysis of proteomic and genomic biomarkers, announced today that they have entered into a collaboration to determine the feasibility of using peripheral blood to perform IncellDx’s Quantitative PD-L1 assay (OncoTect iO™) on Celsee’s rare cell isolation and analysis platforms, that may predict therapy response to metastatic cancers. During the studies, Celsee Diagnostics will perform the OncoTect iO quantitative PD-L1 assay on peripheral blood samples from metastatic lung cancer patients using the Celsee™ PREP400 and the Celsee ANALYZER. custodia cover samsung These data will then be compared with OncoTect iO data from primary tumors to assess the potential similarities and differences between cancer cells in peripheral blood and tumor tissue dissociated with IncellDx’s IncellPREP (IVD) kit. Ultimately, this analysis will be used to tailor therapy that more closely addresses the clones capable of spreading. “Immunotherapy shows great promise for the treatment of specific types of metastatic cancer. This collaborative study will continue to validate the use of the Celsee PREP platform for detecting a wide range of surface biomarkers on rare cells in the blood, and substantiate the value of the platform for use in prognosis and therapeutic decision making,” stated Celsee Diagnostics’ Chief Executive Officer Kalyan Handique, Ph.D. “Immuno-oncology is in need of non-subjective, quantitative assay approaches that can incorporate simultaneous protein, RNA in situ hybridization, and DNA cell cycle determinations as delivered by the IncellDx assay platform. Our platform is well suited for the Celsee microfluidic chip system and possibly extends the applications from blood to rare-event detection in primary tumors,” said IncellDx’s CEO and Founder, Bruce Patterson, M.D. The technologic synergies between the two companies can certainly enable application to additional tumor types. About Celsee Diagnostics Celsee Diagnostics, a privately-held Michigan-based company, develops automated systems for rare CTC enrichment and single-cell analysis. The company’s platform for research and clinical diagnostics development will allow healthcare professionals more time to focus on their patients’ therapeutic treatment and outcomes. fundas huawei y7 2019 The label-free Celsee PREP platforms perform all the required processing steps to isolate and execute downstream single-cell analysis including immunochemistry, DNA FISH and mRNA FISH, while the Celsee ANALYZER scans and analyzes the prepared slide automatically. fundas iphone 11 About IncellDx IncellDx is a single cell diagnostic company committed to advancing Precision Medicine by offering transformative diagnostic and prognostic clinical patient information based on an innovative technology platform that enables simultaneous, quantitative, single cell protein analysis, multiplex RNA in situ hybridization, and DNA cell cycle analysis. fundas samsung galaxy j5 Visit www.incelldx.com for more information. fundas iphone x xs Media Contact: Nicole Litchfield Bioscribe, Inc.

CONTACT A SPECIALIST

  • Systems
  • Applications
  • Support
  • News & Events
  • About Us
  • Careers
  • Contact Us
  • Distributors

© 2020 Celsee, Inc. – All Rights Reserved Privacy Policy – Terms of Use 100 Phoenix Drive – Suite 321 Ann Arbor, MI 48108

Contact us today 866.748.1448 248.319.6919


LinkedInTwitterInstagram

We use cookies in order to improve and customize your browsing experience. By continuing, you are consenting to our privacy policy. Accept Decline Read our Privacy Policy
Necessary
Always Enabled

This is an necessary category.

Non Necessary

This is an non-necessary category.

Save & Accept

Contact Tech Support


 

Technical Support


Contact Sales


Terms of Use | Privacy Policy

Contact Us


Terms of Use | Privacy Policy

Let’s Talk


Fill out this form to have a Celsee representative contact you about pricing, products, and other details regarding the Genesis System.

Terms of Use | Privacy Policy

Get the Latest Updates on Life Sciences Technology Delivered To Your Inbox

Terms of Use | Privacy Policy

Technical Support


Contact Us


 

Terms of Use | Privacy Policy

Be Connected to a Distributor

Contact Us About the Genesis System

If you would like to have a Celsee representative contact you about pricing, products, and other details regarding the Genesis System, please fill out the form below:

Terms of Use | Privacy Policy

Submit an Application

Submit an Application

For consideration, please fill the form out below. No phone calls, please. Only qualified candidates will be contacted.

[contact-form-7 id=”1065″ title=”Job Application Form”]

*Celsee, Inc. is an equal opportunity employer, and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability status, protected veteran status or any other characteristic protected by law.